Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report)’s stock price dropped 4.5% during mid-day trading on Tuesday . The company traded as low as $6.28 and last traded at $6.32. Approximately 13,134 shares were traded during trading, a decline of 98% from the average daily volume of 582,739 shares. The stock had previously closed at $6.6170.
Analyst Ratings Changes
CLPBY has been the topic of a number of recent analyst reports. Sanford C. Bernstein upgraded shares of Coloplast A/S to a “hold” rating in a research note on Wednesday, January 28th. The Goldman Sachs Group cut shares of Coloplast A/S from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 7th. Finally, Kepler Capital Markets upgraded shares of Coloplast A/S to a “strong-buy” rating in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold”.
Check Out Our Latest Stock Analysis on CLPBY
Coloplast A/S Stock Performance
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. The firm had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a net margin of 7.46% and a return on equity of 31.96%. On average, sell-side analysts forecast that Coloplast A/S Sponsored ADR will post 0.4 earnings per share for the current fiscal year.
About Coloplast A/S
Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.
In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.
See Also
- Five stocks we like better than Coloplast A/S
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
- 3 Defense Giants Boosting Dividends as Shares Take a Ride
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
